Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 
Datenbankrecherche:

 

Changes to DNA on-off switches affect cells' ability to repair breaks, respond to chemotherapy

04.02.2013
Double-strand breaks in DNA happen every time a cell divides and replicates.

Depending on the type of cell, that can be pretty often. Many proteins are involved in everyday DNA repair, but if they are mutated, the repair system breaks down and cancer can occur. Cells have two complicated ways to repair these breaks, which can affect the stability of the entire genome.

Roger A. Greenberg, M.D., Ph.D., associate investigator, Abramson Family Cancer Research Institute and associate professor of Cancer Biology at the Perelman School of Medicine, University of Pennsylvania, together with postdoctoral researcher Jiangbo Tang Ph.D. and colleagues, found a key determinant in the balance between two proteins, BRCA1 and 53BP1, in the DNA repair machinery. Breast and ovarian cancer are associated with a breakdown in the repair systems involving these proteins. Their findings appear in the latest online issue of Nature Structural & Molecular Biology.

The two proteins, BRCA1 and 53BP1, control which of two cell-repair mechanisms will be used: homologous recombination or non-homologous end-joining, technically speaking. This competition has proven to be a key factor in determining whether a cell becomes cancer prone as well as how a cancer cell will respond to chemotherapy.

The key step of the balance is acetylation, the chemical process of adding a compound called an acetyl group to other cellular molecules.

The researchers asked what cell signals determine whether BRCA or 53BP1 predominates at a DNA break site.

DNA in the nucleus is tightly packed around proteins called histones. Acetylation at a specific spot on histone H4 determines the answer. If H4 is acetylated at a specific location, then 53BP1 binding near the broken DNA region is strongly reduced. This leaves BRCA1 free to do the work, kicking in the homologous recombination tool to repair the break.

On the other hand, if acetylation is reduced, 53BP1 outcompetes BRCA1 at a break and the non-homologous end-joining tool repairs the break.

This mechanism can help explain resistance to a promising chemotherapy called PARP inhibition seen in patients and mouse models with BRCA1 mutations. Work from several other research teams surprisingly has shown that if neither BRCA nor 53BP1 are available, then the homologous recombination system goes into action even in the absence of BRCA1 and BRCA1 mutant cancer cells become resistant to PARP inhibitors.

Because of this, Greenberg says, there are some possible applications for making PARP chemotherapy more sensitive: "If you could inhibit specific acetylation events, then a patient's response to PARP inhibitors might be enhanced by hyperactivating 53BP1 binding to breaks in the context of BRCA1 deficient cancers. What's more, measuring the levels of acetylation at H4 might predict how responsive an individual is to PARP inhibitors."

"The story didn't fall into place the way we thought it would," says Greenberg. "We didn't realize that it was a combination of two epigenetic marks that drives the repair system. However, we were able to show that 53BP1 doesn't bind well to regions of histone H4 that are acetylated at a specific location on H4. Collaboration with Georges Mer, a structural biologist at the Mayo Clinic, helped provide the molecular basis for these findings. We think there will be further complexity to this regulation, creating the possibility for the discovery of additional mechanisms that regulate DNA repair pathways and response to therapy and potential new targets for diagnosis and therapy."

Co-authors are Nam Woo Cho, Erica M. Manion, Niraj M. Shanbhag, all from Penn, and Gaofeng Cui, Maria Victoria Botuyan, and Georges Mer, from the Department of Biochemistry and Molecular Biology, Mayo Clinic.

The research was supported by the National Cancer Institute (1R01CA138835-01, 1R01CA132878, P50CA116201), a Research Scholar Grant from the American Cancer Society, a DOD Breast Cancer Idea Award, a UPENN-FCCC SPORE Pilot Grant, and funds from the Abramson Family Cancer Research Institute and Basser Research Center for BRCA.

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital — the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2011, Penn Medicine provided $854 million to benefit our community.

Karen Kreeger | EurekAlert!
Further information:
http://www.uphs.upenn.edu

More articles from Life Sciences:

nachricht New Technique Maps Elusive Chemical Markers on Proteins
03.07.2015 | Salk Institute for Biological Studies

nachricht New approach to targeted cancer therapy
03.07.2015 | CECAD - Cluster of Excellence at the University of Cologne

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Forschungsschiff Heincke seit 25 Jahren im Dienst der Wissenschaft

Ein Vierteljahrhundert alt, über 900.000 Kilometer (488.842 nautische Meilen) gefahren und trotzdem auf dem neuesten wissenschaftlichen und technischen Stand: Die Indienststellung des Forschungsschiffes Heincke jährt sich am 8. Juli 2015 zum 25. Mal.

Wissenschaftler des Alfred-Wegener-Instituts, Helmholtz-Zentrum für Polar- und Meeresforschung (AWI), das die Heincke betreibt, nehmen ebenso regelmäßig an...

Im Focus: Solardächer produzieren Strom für Fahrzeuge

Studentische Industriekooperation zwischen HAW Hamburg und Webasto erarbeitet Ergebnisse für EU-Zertifizierungsprozess von Solardächern zur Verbesserung der Öko-Bilanz von Fahrzeugen.

Unter der Leitung von Dr.-Ing. Volker Skwarek, Professor für technische Informatik an der HAW Hamburg, erarbeiteten sechs Studierende des...

Im Focus: Viaducts with wind turbines, the new renewable energy source

Wind turbines could be installed under some of the biggest bridges on the road network to produce electricity. So it is confirmed by calculations carried out by a European researchers team, that have taken a viaduct in the Canary Islands as a reference. This concept could be applied in heavily built-up territories or natural areas with new constructions limitations.

The Juncal Viaduct, in Gran Canaria, has served as a reference for Spanish and British researchers to verify that the wind blowing between the pillars on this...

Im Focus: Aus alt mach neu - Rohstoffquelle Elektroschrott

Der Markt für Unterhaltungselektronik boomt: Rund 60 Millionen Fernsehgeräte wurden im letzten Jahr in Europa verkauft. Früher oder später werden sie zurückkehren – als Elektroschrott.

Die Recycling-Industrie hat darauf reagiert: Kupfer, Aluminium, Eisen- und Edelmetalle sowie ausgewählte Kunststoffe werden bereits wiederverwertet. Allerdings...

Im Focus: Radar schützt vor Weltraummüll

Die Bedrohung im All durch Weltraummüll ist groß. Aktive Satelliten und Raumfahrzeuge können beschädigt oder zerstört werden. Ein neues, nationales Weltraumüberwachungssystem soll ab 2018 vor Gefahren im Orbit schützen. Fraunhofer-Forscher entwickeln das Radar im Auftrag des DLR Raumfahrtmanagement.

Die »Verkehrssituation« im All ist angespannt: Neben unzähligen Satelliten umkreisen Weltraumtrümmer wie beispielsweise ausgebrannte Raketenstufen und...

Alle Focus-News des Innovations-reports >>>

Anzeige

Anzeige

IHR
JOB & KARRIERE
SERVICE
im innovations-report
in Kooperation mit academics
Veranstaltungen

Flurförderzeuge im Zeichen der Zeit

03.07.2015 | Veranstaltungen

Aktuelles aus Forschung und Betrieb: 27. Deutscher Flammentag

02.07.2015 | Veranstaltungen

Call for ideas: Gute Ideen für bessere Städte

02.07.2015 | Veranstaltungen

 
B2B-VideoLinks
Weitere VideoLinks >>>
Aktuelle Beiträge

Siemens erhält Auftrag für Offshore-Windkraftwerk in Großbritannien

03.07.2015 | Unternehmensmeldung

Flurförderzeuge im Zeichen der Zeit

03.07.2015 | Veranstaltungsnachrichten

Kompakter Time Converter für zuverlässigen Einsatz in rauen Umgebungen

03.07.2015 | Energie und Elektrotechnik